{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:40:36Z","timestamp":1770288036649,"version":"3.49.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01225","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T04:40:53Z","timestamp":1571287253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of Raltegravir-Based Dual Therapy in AIDS Patients: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"10","author":[{"given":"Yinqiu","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118228","article-title":"Raltegravir non-inferior to nucleoside based regimen in second-line therapy with lopinavir\/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection","volume":"10","author":"Amin","year":"2015","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2146\/ajhp100156","article-title":"Management of HIV infection in treatment-naive patients: a review of the most current recommendations","volume":"68","author":"Boyd","year":"2011","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B3","first-page":"115","article-title":"Challenges in the management of osteoporosis and vitamin D deficiency in HIV infection","volume":"21","author":"Brown","year":"2013","journal-title":"Top Antivir. Med."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-1870EEEE","article-title":"Maraviroc for Previously Treated Patients With R5 HIV-1 Infection","volume":"124","author":"Church","year":"2009","journal-title":"Pediatrics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection","volume":"359","author":"Cooper","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2165\/11204590-000000000-00000","article-title":"Raltegravir: in treatment-naive patients with HIV-1 infection","volume":"70","author":"Croxtall","year":"2010","journal-title":"Drugs"},{"key":"B7","article-title":"Guidelines for treatment of HIV infected adults in Europe","year":"2017"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1093\/jac\/dkr269","article-title":"Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimen: 48 week results of the randomized EASIER ANRS 138 trial","volume":"66","author":"Gallien","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(06)69158-7","article-title":"The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings","volume":"368","author":"Gilks","year":"2006","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","article-title":"Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study","volume":"381","author":"Group","year":"2013","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1473-3099(17)30630-8","article-title":"Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial","volume":"18","author":"Hakim","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"Am. J. Kidney Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1310\/hct1303-119","article-title":"A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results","volume":"13","author":"Kozal","year":"2012","journal-title":"HIV Clin. Trials"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/S2352-3018(16)30011-X","article-title":"Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study","volume":"3","author":"La Rosa","year":"2016","journal-title":"Lancet HIV"},{"key":"B18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus Efavirenz regimen in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"Lennox","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study","volume":"46","author":"Markowitz","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1086\/656412","article-title":"Bone disease in HIV infection: a practical review and recommendations for HIV care providers","volume":"51","author":"McComsey","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int. J. Surg."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1097\/QAD.0b013e328348dab0","article-title":"A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)","volume":"25","author":"Nguyen","year":"2011","journal-title":"AIDS"},{"key":"B24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1749-6632.2011.05972.x","article-title":"Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium","volume":"1222","author":"Nguyen","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimen for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1016\/S0140-6736(14)61170-3","article-title":"Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001\/ANRS143 randomised non-inferiority trial","volume":"384","author":"Raffi","year":"2014","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1310\/hct1205-255","article-title":"Examination of noninferiority, safety, and tolerability of lopinavir\/ritonavir and raltegravir compared with lopinavir\/ritonavir and tenofovir\/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results","volume":"12","author":"Reynes","year":"2011","journal-title":"HIV Clin. Trials"},{"key":"B29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1089\/aid.2011.0275","article-title":"Lopinavir\/ritonavir combined with raltegravir or tenofovir\/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study","volume":"29","author":"Reynes","year":"2013","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"B30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMra1004180","article-title":"Development of antiretroviral drug resistance","volume":"365","author":"Wainberg","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B31","first-page":"234","article-title":"Evolutionary mechanisms of retroviral persistence","volume":"13","author":"Whitney","year":"2011","journal-title":"AIDS Rev."},{"key":"B32","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach","year":"2013"},{"key":"B33","volume-title":"Global update on HIV treatment 2013: results, impact and opportunities","year":"2013"},{"key":"B34","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach","year":"2016"},{"key":"B35","unstructured":"GenevaWorld Health OrganizationAntiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a public health approach2010"},{"key":"B36","unstructured":"Comparative efficacy and safety of raltegravir-based simplified regimen for people living with HIV infection: a systematic review and meta-analysisS12\n            Yinqiu, Huang\n          Lancet192"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T04:40:56Z","timestamp":1571287256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":36,"alternative-id":["10.3389\/fphar.2019.01225"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01225","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"article-number":"1225"}}